MedTrace Logo

Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients

NCT02327676 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2014-12-30

No results posted yet for this study

Summary

This study evaluates generic emtricitabine(FTC) in Chinese naive children chronic hepatitis B patients. Single group of child patients were enrolled, which include HBeAg positive and negative Chronic hepatitis B(CHB)group.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

Emtricitabine

emtricitabine were given to each patients for 48 weeks

Sponsors & Collaborators

  • Beijing Ditan Hospital

    collaborator OTHER

  • Hebei Medical University Pharmaceutical Factory

    collaborator INDUSTRY

  • National Health and Family Planning Commission, P.R.China

    collaborator OTHER_GOV

  • Asian-Pacific Alliance of Liver Disease, Beijing

    lead OTHER

Principal Investigators

  • Jun Cheng, M.D. · Asian Pacific Alliance of Liver Diseases, Beijing

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-07-31
Completion
2016-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02327676 on ClinicalTrials.gov